Innate immune receptors, key actors in cardiovascular diseases
Entity
UAM. Departamento de Medicina; Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)Publisher
Elsevier on behalf of the American College of Cardiology FoundationDate
2020-07-01Citation
10.1016/j.jacbts.2020.03.015
JACC: Basic to Translational Science 5.7 (2020): 735-749
ISSN
2452-302XDOI
10.1016/j.jacbts.2020.03.015Editor's Version
https://doi.org/10.1016/j.jacbts.2020.03.015Subjects
cardiovascular disease; innate immune system; NLRP3; NOD1; nucleotide-binding oligomerization domain-like receptors; toll-like receptors; MedicinaRights
© 2020 The authorsEsta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
Abstract
Cardiovascular diseases (CVDs) are the leading cause of death in the industrialized world. Most CVDs are associated with increased inflammation that arises mainly from innate immune system activation related to cardiac damage. Sustained activation of the innate immune system frequently results in maladaptive inflammatory responses that promote cardiovascular dysfunction and remodeling. Much research has focused on determining whether some mediators of the innate immune system are potential targets for CVD therapy. The innate immune system has specific receptors—termed pattern recognition receptors (PRRs)—that not only recognize pathogen-associated molecular patterns, but also sense danger-associated molecular signals. Activation of PRRs triggers the inflammatory response in different physiological systems, including the cardiovascular system. The classic PRRs, toll-like receptors (TLRs), and the more recently discovered nucleotide-binding oligomerization domain-like receptors (NLRs), have been recently proposed as key partners in the progression of several CVDs (e.g., atherosclerosis and heart failure). The present review discusses the key findings related to the involvement of TLRs and NLRs in the progression of several vascular and cardiac diseases, with a focus on whether some NLR subtypes (nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain-containing receptor 3 and nucleotide-binding oligomerization domain-containing protein 1) can be candidates for the development of new therapeutic strategies for several CVDs.
Files in this item
Google Scholar:Jaén, Rafael I.
-
Val-Blasco, Almudena
-
Prieto, Patricia
-
Gil-Fernández, Marta
-
Smani, Tarik
-
López-Sendón, José Luis
-
Delgado, Carmen
-
Boscá, Lisardo
-
Fernández-Velasco, María
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Tumor stem cells fuse with monocytes to form highly invasive tumor-hybrid cells
Aguirre, Luis Augusto; Montalbán-Hernández, Karla; Avendaño-Ortiz, José; Marín, Elvira; Lozano, Roberto; Toledano, Víctor; Sánchez-Maroto, Laura; Terrón, Verónica; Valentín, Jaime; Pulido, Elisa; Casalvilla, José Carlos; Rubio, Carolina; Diekhorst, Luke; Laso-García, Fernando; del Fresno, Carlos; Collazo-Lorduy, Ana; Jiménez-Munarriz, Beatriz; Gómez-Campelo, Paloma; Llanos-González, Emilio; Fernández-Velasco, María; Rodríguez-Antolín, Carlos; Pérez de Diego, Rebeca; Cantero-Cid, Ramón; Hernádez-Jimenez, Enrique; Álvarez, Enrique; Rosas, Rocío; dies López-Ayllón, Blanca; de Castro, Javier; Wculek, Stefanie K.; Cubillos-Zapata, Carolina; Ibáñez de Cáceres, Inmaculada; Díaz-Agero, Prudencio; Gutiérrez Fernández, María; Paz de Miguel, María; Sancho, David; Schulte, Leon; Perona, Rosario; Belda-Iniesta, Cristóbal; Boscá, Lisardo; López-Collazo, Eduardo
2020-06-16